Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cladribine, Cytarabine, and Idarubicin in Relapsed AML
NCT00126321Phase 2Unknown
- Sponsor
- University Hospital Bonn
- Start
- Nov 2004
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cladribine in acute myeloid leukemia (AML), sponsored by University Hospital Bonn. Primary endpoints: Toxicity according to NCI/CTC and Rate of Complete Remission. Status: unknown.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00126321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126321.